Advice
NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency.
The information provided includes a description of the technology, how it’s used and its potential role in the treatment pathway. A MIB also includes a review of relevant published evidence and the likely costs of using the technologies, but they are not NICE guidance and do not make any recommendations on the value of using the technologies.